BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to HT-29 cell line is 458
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0085 | 31285270 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting | NA | 0.64 | 0.0085 | 25884645 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.64 | 0.0085 | 27748801 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.64 | 0.0085 | 27748801 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.64 | 0.0085 | 27748801 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.64 | 0.0085 | 27748801 |
| DPP4 | 3009 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.64 | 0.0085 | 25884645 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.211 | 31285270 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by qPCR and Western Blotting | NA | 0.64 | 0.211 | 30337351 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by qRT-PCR and SFA | NA | 0.64 | 0.211 | 28755485 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.64 | 0.211 | 27748801 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.64 | 0.211 | 27748801 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.64 | 0.211 | 27748801 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.64 | 0.211 | 27748801 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.64 | 0.211 | 30772447 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.64 | 0.211 | 27556511 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.64 | 0.211 | 27556511 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.64 | 0.211 | 24970802 |
| EPCAM | 11529 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.64 | 0.211 | 26634106 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0753 | 31285270 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.64 | 0.0753 | 22384170 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by qPCR and Western Blotting | NA | 0.64 | 0.0753 | 30337351 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.64 | 0.0753 | 32037723 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and IF staining | NA | 0.64 | 0.0753 | 24789370 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IF staining and FACs | NA | 0.64 | 0.0753 | 22745705 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and Western Blotting | NA | 0.64 | 0.0753 | 24039918 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.64 | 0.0753 | 27894099 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting followed by SFA | NA | 0.64 | 0.0753 | 31964531 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and IF staining | NA | 0.64 | 0.0753 | 26745821 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.64 | 0.0753 | 33744851 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.64 | 0.0753 | 35267511 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.64 | 0.0753 | 30772447 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.64 | 0.0753 | 29902974 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.64 | 0.0753 | 29660380 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and RT-PCR | NA | 0.64 | 0.0753 | 28464221 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qPCR | NA | 0.64 | 0.0753 | 28825721 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.64 | 0.0753 | 21435460 |
| LGR5 | 4504 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.64 | 0.0753 | 22329848 |
| MYC | 7553 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.6 | 0.1304 | 27520449 |
| SOX2 | 11195 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.6 | 0.5695 | 20630067 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.1135 | 22384170 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.6 | 0.1135 | 30772447 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.1135 | 21130073 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.6 | 0.1135 | 27556511 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.1135 | 27556511 |
| BMI1 | 1066 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.1135 | 29312609 |
| DCLK1 | 2700 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by qPCR and Western Blotting | NA | 0.6 | 0.0159 | 30337351 |
| DCLK1 | 2700 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.0159 | 30144515 |
| DCLK1 | 2700 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting followed by SFA | NA | 0.6 | 0.0159 | 31964531 |
| LRIG1 | 17360 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by qPCR and Western Blotting | NA | 0.6 | 0.0053 | 30337351 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.1304 | 22384170 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.1304 | 30944638 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IHC staining | NA | 0.6 | 0.1304 | 26918725 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.6 | 0.1304 | 27748801 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.6 | 0.1304 | 27748801 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.1304 | 21130073 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.1304 | 26634106 |
| MYC | 7553 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.1304 | 29312609 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by qPCR and Western Blotting | NA | 0.6 | 0.5461 | 30337351 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.6 | 0.5461 | 30774996 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and RT-PCR | NA | 0.6 | 0.5461 | 31120140 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.6 | 0.5461 | 33819194 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IHC staining | NA | 0.6 | 0.5461 | 26918725 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.5461 | 35267511 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.6 | 0.5461 | 30772447 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by SFA | NA | 0.6 | 0.5461 | 32037723 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.6 | 0.5461 | 29902974 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.5461 | 21130073 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.5461 | 27556511 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.5461 | 31544978 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.5461 | 26634106 |
| NANOG | 20857 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by RT-PCR | NA | 0.6 | 0.5461 | 30209760 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.6448 | 22384170 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.6 | 0.6448 | 30774996 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and RT-PCR | NA | 0.6 | 0.6448 | 31120140 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.6 | 0.6448 | 33819194 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.6448 | 33667839 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.6448 | 30944638 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and IF staining | NA | 0.6 | 0.6448 | 26745821 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IHC staining | NA | 0.6 | 0.6448 | 26918725 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.6448 | 35267511 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.6 | 0.6448 | 27748801 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.6 | 0.6448 | 27748801 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.6 | 0.6448 | 27748801 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.6 | 0.6448 | 27748801 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by SFA | NA | 0.6 | 0.6448 | 32037723 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.6448 | 21130073 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.6 | 0.6448 | 27556511 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.6448 | 27556511 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.6448 | 31544978 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.6448 | 26634106 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.6448 | 29312609 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by RT-PCR | NA | 0.6 | 0.6448 | 30209760 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.6 | 0.6448 | 21435460 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.7582 | 22384170 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR and Western Blotting followed by FACs | NA | 0.6 | 0.7582 | 26002465 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.6 | 0.7582 | 21596996 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and Western Blotting | NA | 0.6 | 0.7582 | 34798428 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and Western Blotting followed by SFA | NA | 0.6 | 0.7582 | 31964531 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and Western Blotting | NA | 0.6 | 0.7582 | 30944638 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting | NA | 0.6 | 0.7582 | 22623141 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by SFA and Western Blotting | NA | 0.6 | 0.7582 | 27894099 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting followed by FACs | NA | 0.6 | 0.7582 | 20023382 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA followed by IF staining | NA | 0.6 | 0.7582 | 33819194 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and IHC staining | NA | 0.6 | 0.7582 | 26918725 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by IF staining | NA | 0.6 | 0.7582 | 30758710 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IF staining and FACs | NA | 0.6 | 0.7582 | 22745705 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by CFA and SFA and qRT-PCR | NA | 0.6 | 0.7582 | 35392530 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and CFA followed by SFA and RT-PCR | NA | 0.6 | 0.7582 | 29312609 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and RT-PCR followed by SFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 21130073 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by qRT-PCR | NA | 0.6 | 0.7582 | 20333645 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SP assay and qRT-PCR and Tumorigenicity assay | NA | 0.6 | 0.7582 | 17932721 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting | NA | 0.6 | 0.7582 | 35115900 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and IF staining | NA | 0.6 | 0.7582 | 24039918 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IF staining | NA | 0.6 | 0.7582 | 28188489 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.6 | 0.7582 | 27748801 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.6 | 0.7582 | 27748801 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.6 | 0.7582 | 27748801 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.6 | 0.7582 | 27748801 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR | NA | 0.6 | 0.7582 | 29158786 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.6 | 0.7582 | 30772447 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | RT-PCR | NA | 0.6 | 0.7582 | 24323901 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.6 | 0.7582 | 29902974 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.7582 | 32037723 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.6 | 0.7582 | 27556511 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.7582 | 27556511 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.7582 | 31544978 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.7582 | 31835579 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 33744851 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.6 | 0.7582 | 34151658 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs | NA | 0.6 | 0.7582 | 33568147 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 33667839 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by FACs and SFA | NA | 0.6 | 0.7582 | 32367652 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil+Oxaliplatin | FACs | NA | 0.6 | 0.7582 | 21774804 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 22329848 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 22329848 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 24760019 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 30947381 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.6 | 0.7582 | 32108197 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | FACs | NA | 0.6 | 0.7582 | 32108197 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.6 | 0.7582 | 32729895 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.6 | 0.7582 | 21694723 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.6 | 0.7582 | 27520449 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and Tumorigenicity assay followed by SP assay | NA | 0.6 | 0.7582 | 21826669 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 26745821 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 30603407 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31285270 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31662289 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31904143 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 31120140 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs | NA | 0.6 | 0.7582 | 19699770 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by SFA | NA | 0.6 | 0.7582 | 30337351 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | SFA and FACs | NA | 0.6 | 0.7582 | 26527315 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 20630067 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 26506839 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 28825721 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 30770752 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.6 | 0.7582 | 21670985 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.6 | 0.7582 | 30770752 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by SP assay and FACs | NA | 0.6 | 0.7582 | 31255531 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by FACs | NA | 0.6 | 0.7582 | 21720213 |
| PROM1 | 9454 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by FACs | NA | 0.6 | 0.7582 | 30209760 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.5695 | 22384170 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.6 | 0.5695 | 30774996 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.6 | 0.5695 | 33819194 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.5695 | 35392530 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.5695 | 30944638 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and IF staining | NA | 0.6 | 0.5695 | 26745821 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IHC staining | NA | 0.6 | 0.5695 | 26918725 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.5695 | 35267511 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by SFA | NA | 0.6 | 0.5695 | 32037723 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.5695 | 21130073 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.5695 | 26634106 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by RT-PCR | NA | 0.6 | 0.5695 | 30209760 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.6 | 0.5695 | 21435460 |
| ALDH1A1 | 402 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.684 | 27520449 |
| CD44 | 1681 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.48 | 1 | 27520449 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.0583 | 21596996 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil+Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 0.0583 | 22761031 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.48 | 0.0583 | 30772447 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and RT-PCR | NA | 0.48 | 0.0583 | 28464221 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qPCR | NA | 0.48 | 0.0583 | 26506839 |
| ALCAM | 400 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.48 | 0.0583 | 27520449 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.684 | 32037723 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.684 | 21596996 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | ALDEFLUOR assay followed by SFA and RT-PCR | NA | 0.48 | 0.684 | 28464221 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR and ALDEFLUOR assay | NA | 0.48 | 0.684 | 30774996 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33667839 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 30144515 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting | NA | 0.48 | 0.684 | 29235568 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.48 | 0.684 | 21694723 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.684 | 33744851 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.684 | 35392530 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR | NA | 0.48 | 0.684 | 28565875 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.48 | 0.684 | 30772447 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.48 | 0.684 | 29902974 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.684 | 21435460 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Paclitaxel | ALDEFLUOR assay | NA | 0.48 | 0.684 | 23327190 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | ALDEFLUOR assay followed by CFA | NA | 0.48 | 0.684 | 32108197 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 27927191 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 30410666 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and CFA | NA | 0.48 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 26634106 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.48 | 0.684 | 21670985 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 21720213 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 1 | 21596996 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 1 | 31544978 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA followed by IF staining | NA | 0.48 | 1 | 33819194 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by IF staining and SFA | NA | 0.48 | 1 | 31285270 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and IHC staining | NA | 0.48 | 1 | 26918725 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IF staining and FACs | NA | 0.48 | 1 | 22745705 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by CFA and SFA and qRT-PCR | NA | 0.48 | 1 | 35392530 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and CFA followed by SFA and RT-PCR | NA | 0.48 | 1 | 29312609 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by qRT-PCR and SFA | NA | 0.48 | 1 | 28755485 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by FACs | NA | 0.48 | 1 | 29158786 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and qPCR | NA | 0.48 | 1 | 26506839 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil+Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 1 | 22761031 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27894099 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil+Oxaliplatin | Western Blotting followed by SFA | NA | 0.48 | 1 | 22072622 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 1 | 33744851 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR | NA | 0.48 | 1 | 28565875 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.48 | 1 | 30772447 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.48 | 1 | 32037723 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 27556511 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.48 | 1 | 29457276 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.48 | 1 | 34151658 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 33667839 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 21701559 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil+Oxaliplatin | FACs | NA | 0.48 | 1 | 21774804 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 22329848 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.48 | 1 | 24323901 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 24760019 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 26136074 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | FACs | NA | 0.48 | 1 | 26136074 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.48 | 1 | 32729895 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.48 | 1 | 24970802 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.48 | 1 | 27520449 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.48 | 1 | 31662289 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA | NA | 0.48 | 1 | 31904143 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 31120140 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs | NA | 0.48 | 1 | 27932392 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and FACs | NA | 0.48 | 1 | 27556511 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 20630067 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 26634106 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 27556511 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 28825721 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 28825721 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.48 | 1 | 30770752 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.48 | 1 | 21670985 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.48 | 1 | 30770752 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 30250604 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by FACs | NA | 0.48 | 1 | 30209760 |
| IL33 | 16028 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.0011 | 28249897 |
| MACsC1 | 30215 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 30082743 |
| PRX | 13797 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 34798428 |
| RAB27A | 9766 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 27556511 |
| RAB27A | 9766 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.48 | 0.0032 | 27556511 |
| RSPO2 | 28583 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 27158331 |
| SRXN1 | 16132 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 34798428 |
| PRDX2 | 9353 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by Western Blotting and SFA | NA | 0.4 | 0.0074 | 27894099 |
| PRDX2 | 9353 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by IF staining | NA | 0.4 | 0.0074 | 33819194 |
| CD24 | 1645 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.32 | 0.456 | 27520449 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by FACs | NA | 0.32 | 0.456 | 29158786 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.32 | 0.456 | 34151658 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.32 | 0.456 | 22329848 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.32 | 0.456 | 24323901 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.32 | 0.456 | 24760019 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs and SFA | NA | 0.32 | 0.456 | 27520449 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 30770752 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by FACs and SP assay | NA | 0.32 | 0.456 | 30770752 |
| KLF4 | 6348 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.0891 | 31120140 |
| KLF4 | 6348 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.32 | 0.0891 | 30772447 |
| KLF4 | 6348 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR followed by SFA | NA | 0.32 | 0.0891 | 32037723 |
| KLF4 | 6348 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0891 | 31544978 |
| KLF4 | 6348 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.32 | 0.0891 | 26634106 |
| NR5A2 | 7984 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | qRT-PCR and FACs followed by SFA | NA | 0.32 | 0.0042 | 32037723 |
| ALDH1A3 | 409 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting | NA | 0.28 | 0.0201 | 29235568 |
| ALDH1A3 | 409 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and FACs | NA | 0.28 | 0.0201 | 24039918 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 35392530 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0647 | 29457276 |
| CXCR4 | 2561 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0498 | 27894099 |
| CXCR4 | 2561 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.28 | 0.0498 | 30772447 |
| CXCR4 | 2561 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.28 | 0.0498 | 21130073 |
| CXCR4 | 2561 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | FACs | NA | 0.28 | 0.0498 | 24323901 |
| CXCR4 | 2561 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | MACs followed by SFA | NA | 0.28 | 0.0498 | 30337351 |
| HMGB1 | 4983 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31255531 |
| PCNA | 8729 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31255531 |
| PTEN | 9588 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and Western Blotting | Down | 0.28 | 0.0053 | 23894315 |
| SCD | 10571 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0127 | 33430034 |
| SCD | 10571 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0127 | 31835579 |
| SNAI1 | 11128 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 33667839 |
| SNAI1 | 11128 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and Western Blotting | NA | 0.28 | 0.0212 | 24039918 |
| SNAI2 | 11094 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 33667839 |
| SNAI2 | 11094 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and Western Blotting | NA | 0.28 | 0.0159 | 24039918 |
| SOX9 | 11204 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0244 | 31964531 |
| TWIST1 | 12428 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0191 | 33667839 |
| WNT1 | 12774 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0074 | 30944638 |
| CCNH | 1594 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Down | 0.24 | 0.0011 | 27932392 |
| CDK7 | 1778 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Down | 0.24 | 0.0011 | 27932392 |
| DDB1 | 2717 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Down | 0.24 | 0.0021 | 27932392 |
| DDB2 | 2718 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| EME1 | 24965 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| ERCC2 | 3434 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| ERCC3 | 3435 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Down | 0.24 | 0.0011 | 27932392 |
| LIG1 | 6598 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| MBD4 | 6919 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| MIR105-1 | 31492 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 21130073 |
| MIR151A | 31762 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21130073 |
| MIR151A | 31762 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21130073 |
| MIR155 | 31542 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 21130073 |
| MIR16-2 | 31546 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MIR181B1 | 31550 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MIR185 | 31556 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MIR221 | 31601 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 21130073 |
| MIR31 | 31630 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0064 | 21130073 |
| MIR320D1 | 35386 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21130073 |
| MIR423 | 31880 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 21130073 |
| MIR429 | 13784 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 21130073 |
| MIR455 | 32344 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MIR455 | 32344 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MIR494 | 32084 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 21130073 |
| MIR548D1 | 32801 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 21130073 |
| MIR636 | 32892 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 21130073 |
| MIR744 | 33658 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21130073 |
| MLH1 | 7127 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| MSH2 | 7325 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| POLE | 9177 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| POLL | 9184 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| RAD51 | 9817 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0032 | 27932392 |
| RAD52 | 9824 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| RFC1 | 9969 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0032 | 27932392 |
| SMUG1 | 17148 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| TEK | 11724 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 17932721 |
| TOP3A | 11992 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0011 | 27932392 |
| UNG | 12572 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0032 | 27932392 |
| XPC | 12816 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0021 | 27932392 |
| XRCC6 | 4055 | HTM/LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | Transcriptomics followed by qPCR | Up | 0.24 | 0.0053 | 27932392 |
| ASCL2 | 739 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0053 | 27520449 |
| ABCB1 | 40 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.2 | 0.0604 | 26206183 |
| ABCB1 | 40 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.2 | 0.0604 | 29902974 |
| ABCB1 | 40 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0604 | 30209760 |
| ABCC1 | 51 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.2 | 0.0212 | 26206183 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | 5-Fluorouracil | qRT-PCR | NA | 0.2 | 0.1739 | 30772447 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR | NA | 0.2 | 0.1739 | 26206183 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.1739 | 21130073 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.2 | 0.1739 | 27556511 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qPCR | NA | 0.2 | 0.1739 | 28825721 |
| ABCG2 | 74 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 27556511 |
| ALDH1A2 | 15472 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qPCR | NA | 0.2 | 0.0117 | 28825721 |
| ASCL2 | 739 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0053 | 32037723 |
| ASCL2 | 739 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 31544978 |
| DNAJB8 | 23699 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.0021 | 24450541 |
| EPHB2 | 3393 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.2 | 0.0011 | 27748801 |
| EPHB2 | 3393 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.2 | 0.0011 | 27748801 |
| FURIN | 8568 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| FURIN | 8568 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| GATA6 | 4174 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR and CFA | NA | 0.2 | 0.0021 | 31544978 |
| ITGB1 | 6153 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Docetaxel | qRT-PCR | NA | 0.2 | 0.018 | 27748801 |
| ITGB1 | 6153 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | Oxaliplatin | qRT-PCR | NA | 0.2 | 0.018 | 27748801 |
| ITGB1 | 6153 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.2 | 0.018 | 22329848 |
| JADE3 | 22982 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0011 | 29660380 |
| JAG1 | 6188 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0117 | 31835579 |
| KLF5 | 6349 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0042 | 29312609 |
| LRP5 | 6697 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0042 | 31835579 |
| MIR127 | 31509 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.2 | 0.0042 | 33744851 |
| MIR21 | 31586 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0085 | 23894315 |
| MSI1 | 7330 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and qRT-PCR | NA | 0.2 | 0.0201 | 27556511 |
| MSI1 | 7330 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0201 | 27556511 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0477 | 35392530 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0477 | 21130073 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qPCR | NA | 0.2 | 0.0477 | 26506839 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0477 | 31835579 |
| PCSK6 | 8569 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35267511 |
| PCSK6 | 8569 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35267511 |
| PCSK7 | 8748 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| PCSK7 | 8748 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| WNT2 | 12780 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0032 | 21130073 |
| MME | 7154 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.12 | 0.0053 | 20630067 |
| MME | 7154 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs | NA | 0.12 | 0.0053 | 22329848 |
| YAP1 | 16262 | LTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA and CFA followed by FACs | NA | 0.12 | 0.0117 | 29312609 |
| ACAN | 319 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| ADH1A | 249 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| ADH1C | 251 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| ADRA2A | 281 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| AGT | 333 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| AKR1B10 | 382 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 27520449 |
| ASRGL1 | 16448 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0053 | 20630067 |
| ATP6V1C2 | 18264 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| BAMBI | 30251 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| BDNF | 1033 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0053 | 17932721 |
| BGN | 1044 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| BMP3 | 1070 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| CCDC198 | 20189 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| CCND1 | 1582 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0201 | 27520449 |
| CD200 | 7203 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| CD3D | 1673 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| CD4 | 1678 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| CD8A | 1706 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| CD8B | 1707 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| CDH2 | 1759 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0085 | 20630067 |
| CEMIP | 29213 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| CLDN1 | 2032 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 27520449 |
| COL2A1 | 2200 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| COL9A1 | 2217 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| CTTNBP2 | 15679 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| DHH | 2865 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| DKK1 | 2891 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| DLL1 | 2908 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0032 | 20630067 |
| DLL3 | 2909 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| DTX1 | 3060 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| DYNC1I1 | 2963 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| EPHB3 | 3394 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 27520449 |
| F2 | 3535 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| FGF1 | 3665 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0032 | 20630067 |
| FGF3 | 3681 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| FZD1 | 4038 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0042 | 20630067 |
| GABRP | 4089 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| GDF2 | 4217 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| GJB1 | 4283 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| GJB1 | 4283 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| GPC3 | 4451 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| GPC4 | 4452 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| HLA-DMB | 4935 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| HSPA12A | 19022 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| IGF2 | 5466 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| KIF12 | 21495 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| KLF9 | 1123 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 27520449 |
| KRT80 | 27056 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 27520449 |
| LGALS2 | 6562 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| LGR4 | 13299 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 27520449 |
| MMP7 | 7174 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| MTSS1 | 20443 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0042 | 17932721 |
| MYCL | 7555 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 27520449 |
| MYOD1 | 7611 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| NCAM1 | 7656 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0074 | 20630067 |
| NEUROG2 | 13805 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| P3H3 | 19318 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| PADI1 | 18367 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 27520449 |
| PKIB | 9018 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| PLXND1 | 9107 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| PLXND1 | 9107 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| RBM5-AS1 | 48871 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 27520449 |
| S100B | 10500 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| SERPINA6 | 1540 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |
| SLC4A4 | 11030 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| SLC4A4 | 11030 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| SPINK1 | 11244 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 17932721 |
| ST6GAL1 | 10860 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| SYT13 | 14962 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 17932721 |
| TFF1 | 11755 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| TTR | 12405 | HTM | Colon Cancer | Adenocarcinoma | HT-29 | NA | FACs for CSC marker and SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 17932721 |